Skip to main content
Premium Trial:

Request an Annual Quote

Celera Genomics Licenses Cancer Targets from Proteomics Effort to Genentech

NEW YORK, Sept. 28 (GenomeWeb News) - Celera Genomics and Genentech have signed a multi-year agreement to develop new cancer drugs based on targets derived from Celera's proteomics platform, Celera said today.

 

Celera will license to Genentech a number of cell-surface targets that it discovered and validated using its proteomics platform. Genentech plans to validate these further and develop drugs against them. These drugs could be antibodies, antibody fragments, proteins, or small molecule drugs.

 

Celera Genomics will receive progess-dependent milestone payments and royalties on sales of any drugs developed. Celera Diagnostics retains the rights to develop certain diagnostics based on the targets.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.